On June 1, 2017, Cellular Biomedicine Group, Inc. (the “Company”) authorized a share repurchase program (the “Share Repurchase Program”), to which the Company may, from time to time, purchase shares of its common stock for an aggregate purchase price not to exceed $10 million. Share repurchases may be executed in open market transactions to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act. The authorization for the Share Repurchase Program may be terminated by the Company in its discretion at any time.

A copy of the press release is attached as Exhibit 99.1 to this report.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated June 1, 2017

About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information

CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session up +0.05 at 6.40 with 52,598 shares trading hands.